RETA
Income statement / Annual
Last year (2022), Reata Pharmaceuticals, Inc.'s total revenue was $2.22 M,
a decrease of 80.71% from the previous year.
In 2022, Reata Pharmaceuticals, Inc.'s net income was -$311.90 M.
See Reata Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$2.22 M
|
$11.49 M
|
$9.02 M
|
$26.52 M
|
$53.59 M
|
$48.06 M
|
$49.86 M
|
$50.32 M
|
$51.95 M
|
$51.20 M
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$124.40 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$2.22 M |
$11.49 M |
$9.02 M |
-$97.88 M |
$53.59 M |
$48.06 M |
$49.86 M |
$50.32 M |
$51.95 M |
$51.20 M |
| Gross Profit Ratio |
1 |
1 |
1 |
-3.69 |
1 |
1 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$169.84 M
|
$155.99 M
|
$159.08 M
|
$128.11 M
|
$97.29 M
|
$71.27 M
|
$39.45 M
|
$35.14 M
|
$34.31 M
|
$45.25 M
|
| General & Administrative
Expenses |
$109.28 M
|
$99.00 M
|
$75.13 M
|
$58.30 M
|
$32.75 M
|
$23.26 M
|
$16.60 M
|
$13.69 M
|
$11.51 M
|
$13.40 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$109.28 M
|
$99.00 M
|
$75.13 M
|
$58.30 M
|
$32.75 M
|
$23.26 M
|
$16.60 M
|
$13.69 M
|
$11.51 M
|
$13.40 M
|
| Other Expenses |
$1.13 M |
$1.20 M |
$1.14 M |
$932,000.00 |
$431,000.00 |
-$3,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$280.25 M |
$256.20 M |
$235.34 M |
$187.34 M |
$130.47 M |
$94.97 M |
$56.74 M |
$50.65 M |
$48.33 M |
$61.58 M |
| Cost And Expenses |
$280.25 M |
$256.20 M |
$235.34 M |
$311.74 M |
$130.47 M |
$94.97 M |
$56.74 M |
$50.65 M |
$48.33 M |
$61.58 M |
| Interest Income |
$5.99 M |
$177,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$41.77 M |
$53.25 M |
$36.78 M |
$11.20 M |
$6.18 M |
$1.45 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.13 M
|
$1.20 M
|
$1.14 M
|
$932,000.00
|
$431,000.00
|
$437,000.00
|
$682,000.00
|
$1.82 M
|
$2.51 M
|
$2.93 M
|
| EBITDA |
-$269.03 M
|
-$243.51 M
|
-$232.32 M
|
-$278.03 M
|
-$73.91 M
|
-$46.48 M
|
-$6.41 M
|
$1.45 M
|
$6.09 M
|
-$7.49 M
|
| EBITDA Ratio |
-121.4 |
-21.19 |
-24.97 |
-10.72 |
-1.43 |
-0.97 |
-0.13 |
0.03 |
0.12 |
-0.15 |
| Operating Income Ratio
|
-121.91
|
-21.3
|
-25.09
|
-10.76
|
-1.43
|
-0.98
|
-0.14
|
-0.01
|
0.07
|
-0.2
|
| Total Other
Income/Expenses Net |
-$33.89 M
|
-$53.13 M
|
-$43.91 M
|
-$4.94 M
|
-$3.64 M
|
-$1.19 M
|
$428,000.00
|
$32,000.00
|
$86,000.00
|
$36,000.00
|
| Income Before Tax |
-$311.93 M |
-$297.84 M |
-$270.24 M |
-$290.16 M |
-$80.52 M |
-$47.67 M |
-$6.67 M |
-$302,000.00 |
$3.67 M |
-$10.35 M |
| Income Before Tax Ratio
|
-140.76
|
-25.92
|
-29.96
|
-10.94
|
-1.5
|
-0.99
|
-0.13
|
-0.01
|
0.07
|
-0.2
|
| Income Tax Expense |
-$25,000.00 |
-$450,000.00 |
-$22.49 M |
$8,000.00 |
$26,000.00 |
$3,000.00 |
-$441,000.00 |
$1.15 M |
$2.98 M |
$24.76 M |
| Net Income |
-$311.90 M |
-$297.39 M |
-$247.75 M |
-$290.17 M |
-$80.55 M |
-$47.67 M |
-$6.23 M |
-$1.45 M |
$689,000.00 |
-$35.11 M |
| Net Income Ratio |
-140.75 |
-25.88 |
-27.47 |
-10.94 |
-1.5 |
-0.99 |
-0.12 |
-0.03 |
0.01 |
-0.69 |
| EPS |
-8.59 |
-8.19 |
-7.35 |
-9.54 |
-2.91 |
-1.99 |
-0.31 |
-0.26 |
0.13 |
-6.38 |
| EPS Diluted |
-8.59 |
-8.19 |
-7.35 |
-9.54 |
-2.91 |
-1.99 |
-0.31 |
-0.26 |
0.0345 |
-1.76 |
| Weighted Average Shares
Out |
$36.32 M
|
$36.32 M
|
$33.71 M
|
$30.41 M
|
$27.70 M
|
$23.93 M
|
$19.82 M
|
$5.50 M
|
$5.50 M
|
$5.50 M
|
| Weighted Average Shares
Out Diluted |
$36.32 M
|
$36.32 M
|
$33.71 M
|
$30.41 M
|
$27.70 M
|
$23.93 M
|
$19.82 M
|
$5.50 M
|
$20.00 M
|
$20.00 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
